MDND (Mesh Medical Device News Desk) and its FB Page have been receiving a lot of questions about which trials are scheduled to follow Linda Gross v. Ethicon, which on Thursday, February 28 resulted in an $11.1 million award to Linda and Jeff Gross.
The award includes $7.76 million in punitive damages. See story here.
The next mesh defective product trial naming manufacturer C.R. Bard had been set for February but was rescheduled for June 11, 2013 in the Southern District of West Virginia. Here is the URL for the June 11, CR Bard trial. See Order #59.
[Late Add* - that trial has been rescheduled for July 8, 2013 and plaintiffs Donna and Dan Cisson].
Bard is MDL (multidistrict litigation) No. 2187 with 2,101 cases filed as of March 1, 2013.
Judge Joseph R. Goodwin
Others scheduled in the Southern District of West Virginia under The Honorable James Goodwin include:
American Medical Systems (MDL No. 2325), TRIAL DATE- December 3, 2013 = 4,225 cases
Ethicon, Johnson & Johnson (MDL No. 2327), TRIAL DATE - January 14, 2014 = 4,027 cases
Boston Scientific (MDL No. 2326), TRIAL DATE - February 11, 2014 =2,409 cases
Coloplast (MDL No. 2387) TRIAL DATE, not set = 206 cases
This does not take into account the many cases filed in state courts in Connecticut, Massachusetts, California, Rhode Island as well as the 2,182 cases filed against Ethicon in the Superior Court of New Jersey (here) as of March 1, 2013.
Judge Carol Higbee's court (who tried the Linda Gross Ethicon case) tells MDND there is no other Ethicon case scheduled at this time.
Without including various state litigation, the total number of product liability mesh cases exceeds 15,000. Estimates from the legal community are that the number of mesh injury cases will top 20,000 rivaling Vioxx litigation. The awards may run into the billions as well.
MDND (Mesh Medical Device News Desk) (here) and its Facebook Page (here) plan to cover the litigation as it unfolds on using real-time posts and a summation of the day's events on Mesh Medical Device News Desk Legal News link (here).